| Literature DB >> 26141921 |
Daniela Weber1, Michael J Davies2, Tilman Grune3.
Abstract
Protein oxidation is involved in regulatory physiological events as well as in damage to tissues and is thought to play a key role in the pathophysiology of diseases and in the aging process. Protein-bound carbonyls represent a marker of global protein oxidation, as they are generated by multiple different reactive oxygen species in blood, tissues and cells. Sample preparation and stabilization are key steps in the accurate quantification of oxidation-related products and examination of physiological/pathological processes. This review therefore focuses on the sample preparation processes used in the most relevant methods to detect protein carbonyls after derivatization with 2,4-dinitrophenylhydrazine with an emphasis on measurement in plasma, cells, organ homogenates, isolated proteins and organelles. Sample preparation, derivatization conditions and protein handling are presented for the spectrophotometric and HPLC method as well as for immunoblotting and ELISA. An extensive overview covering these methods in previously published articles is given for researchers who plan to measure protein carbonyls in different samples.Entities:
Keywords: 2,4-Dinitrophenylhydrazine; ELISA; Immunoblotting; Protein carbonyls; Sample preparation; Spectrophotometry
Mesh:
Substances:
Year: 2015 PMID: 26141921 PMCID: PMC4506980 DOI: 10.1016/j.redox.2015.06.005
Source DB: PubMed Journal: Redox Biol ISSN: 2213-2317 Impact factor: 11.799
Possible oxidation products of amino acid residues resulting in protein carbonyl formation.
| Proline | Glutamic semialdehyde and other ring opened products |
| Arginine | Glutamic semialdehyde and other side-chain products |
| Lysine | Aminoadipic semialdehyde and other side-chain products |
| Threonine | Carbonyls formed at side chain sites |
| Methionine | Methional |
| Tryptophan | N-formylkynurenine, kynurenine |
| Histidine | 2-Oxo-histidine and ring-opened species |
| Alanine | Formaldehyde and carbonyls from methyl group |
| Valine | Acetone, formaldehyde and carbonyls on side-chain methyl groups |
| Leucine | Isobutyraldehyde, acetone, formaldehyde, and carbonyls on side-chain |
| Aspartate | Glyoxylic acid |
| Isoleucine | Formaldehyde, carbonyls on side-chain |
Fig. 1Protein oxidation resulting in protein carbonyl formation. Reactive oxygen species (ROS) may either react directly with some amino acid residues or lead to oxidative cleavage of the protein backbone. Other possible formation routes of protein carbonyls are via the oxidation of lipids resulting in reactive aldehydes which react with cysteine (Cys), histidine (His), arginine (Arg) and lysine (Lys) residues and thus introduce carbonyl groups and furthermore via the reaction of reducing sugars or their oxidation products with the same residues.
Fig. 2Reaction of protein carbonyl group with 2,4-dinitrophenylhydrazine. The nucleophilic addition, also called condensation reaction, resulting in a 2,4-dinitrophenyl hydrazone is shown for an oxidized lysine residue (aminoadipic semialdehyde). Note that the reaction is accompanied by the loss of one molecule of water.
Fig. 3Flow chart of possibilities to analyze protein carbonyls after DNP derivatization. Several options exist to detect protein carbonyls in a sample, either quantitatively or qualitatively, depending on the research question and laboratory equipment/facilities. The left-hand side shows several ways of the so-called OxyBlot. The proteins can be separated before derivatization or the other way around. Following separation/derivatization, immunoblot is carried out. If separation is performed with 2D PAGE, the immunoblot is not mandatory and is usually followed by mass spectrometry. The right hand side depicts more quantitative methods: the spectrophotometric assay, ELISA and HPLC where standards are commonly used to assess the exact concentration of protein carbonyls in the sample.
Published sample preparation for spectrophotometric determination of protein carbonyls (n.a.: not available, ratio of sample volume to DNP volume).
| Species | Sample preparation | Derivatization conditions | Protein handling | Wave-length | Level | Refs. |
|---|---|---|---|---|---|---|
| (Precipitation, washing, dissolving) | ||||||
| n.a. | Oxidatively modified proteins (>0.5 mg) | 10 mM DNPH (in 2 M HCl or in 6 M guanidine-HCl, pH 2.5)ratio n.a.1 hn.a. if under dark conditions | 20% TCA | Spectrum (360–390 nm) | 0.2–1.0 mol/mol protein | |
| Ratio n.a. | Washing with ethanol–ethyl acetate (1:1) | |||||
| 1 h | 6 M guanidine | |||||
| n.a. if under dark conditions | ||||||
| Human | Heparin plasma | DNPH (concentration n.a.) | n.a. | 360 nm (280 nm) | 1.02 nmol/mg | |
| −80 °C | Ratio n.a. | Washing n.a. | ||||
| Dilution n.a. | Conditions/duration n.a. | Guanidine n.a. | ||||
| Human | Serum | 10 mM DNPH (in 2.5 M HCl) | 20% TCA | n.a. | 2.4±0.21 nmol/mg | |
| −80 °C | Ratio n.a. | Washing with ethanol–ethyl acetate (1:1) | 22,000 M−1/cm | |||
| 1:100 dilution | Duration n.a. | 6 M guanidine | ||||
| Decomplementation at 56 °C for 30 min | n.a. if dark | |||||
| Human | Plasma | n.a. | n.a. | n.a. | 0.48–0.7 nmol/mg | |
| −80 °C | In 96-well plates | |||||
| Concentration n.a. | ||||||
| Human | Plasma of children with juvenile chronic arthritis | 20 mM DNPH | 20% TCA | 360 nm | Patients vs controls: 1.36±0.68 vs 0.807±0.16 nmol/mg | |
| Undiluted plasma | Ratio (1:1) | Washing with ethanol–ethyl acetate (1:1) | ||||
| 1 h | 6 M guanidine | |||||
| Human | Mesenchymal stem cell (hMSCs) suspensions | 10 mM DNPH | 20% TCA (v/v) | 360 nm | 20–70 µmol/103 cells | |
| 30% TCA precipitate resuspended in DNPH | 1 h (37 °C) | Washing with ethanol–ethyl acetate (1:1) | ||||
| Concentration n.a. | Guanidine in 2 mM phosphate buffer | |||||
| Human | Acute promyelocytic leukemia (APL)-derived NB-4 cells soluble protein fraction with protease inhibitors, sonicated | 10 mM DNPH | 20% TCA | 370 nm | ~3.5 nmol/mg | |
| Stored at −20 °C | Ratio (1:6) | Washing with ethanol–ethyl acetate (1:1) | ||||
| Concentration n.a. | 1 h (20 °C) in the dark | 6 M guanidine | ||||
| Mouse | Neutrophil cell lysate in 50 mM potassium phosphate (pH 7.4) | High DNPH (in 2 M HCl) | 20% TCA | 370 nm | 10–30 nmol/mg | |
| Concentration n.a. | Ratio n.a. | Washing with ethanol–ethyl acetate (1:1) | ||||
| 1 h in the dark | 6 M guanidine | |||||
| Mouse | Peritoneal macrophage cell lysate in 50 mM potassium phosphate (pH 7.4) | High DNPH (in 2 M HCl) | 20% TCA | 370 nm | 5–12 µmol/mg | |
| Concentration n.a. | Ratio n.a. | Washing with ethanol–ethyl acetate (1:1) | ||||
| 1 h in the dark | 6 M guanidine | |||||
| Conditions n.a. | ||||||
| Mouse | Brain cortex homogenate extracts in phosphate buffer (pH 7) with DTT and EDTA | DNPH | n.a. | 370 nm in 96-well plate | 0.2–0.4 nmol/mg | |
| Streptomycin substrate (10%) to remove nucleic acids | Ratio, duration and dark conditions n.a. | |||||
| Concentration n.a. | ||||||
| Mouse | Lysate of primary cortical neurons in phosphate buffer (pH 6.5) | 1× DNPH (in 2 M HCl) | 10% TCA | 375 nm | Expressed as fold-increase to controls | |
| Lysis and storage n.a. | Ratio n.a. | Washing with ethanol–ethyl acetate (1:1) | ||||
| Concentration n.a. | 20 min at RT | 6 M guanidine in 20 mM sodium phosphate buffer (pH 6.5) | ||||
| Mouse | Serum and kidney homogenate (in PBS, pH 7.4, containing protease inhibitor cocktail) | 10 mM DNPH (in 2.5 M HCl) | 20% TCA | 370 nm | 3-Fold increase in protein carbonyls in mice treated with tetrachlorethene | |
| Undiluted serum | Ratio (1:4) | Washing with ethanol–ethyl acetate (1:1) | ||||
| 1 h at RT in the dark | 6 M guanidine | |||||
| Rat | EDTA plasma of Sprague Dawley rats | DNPH (concentration n.a.) | 20% TCA | 380 nm | ~3 nmol/mg | |
| −20 °C storage | Ratio n.a. | Washing n.a. | ||||
| Dilution n.a. | 1 h | Guanidine n.a. | ||||
| n.a. if dark | ||||||
| Cow | BSA | 10 mM DNPH | 20% TCA | 360 nm (scan 320–450 nm) | Method description | |
| Concentration n.a. | Ratio (1:5) | Washing with ethanol-ethyl acetate (1:1) | ||||
| 1 h at RT | Solubilization in 0.2% (w/v) SDS/20 mM Tris–Cl, pH 6.8 | |||||
| Cow | Aortic endothelial cells | 0.2% DNPH (≙ 10 mM) (in 2 M HCl) ratio n.a.for 1 h in the dark | 20% TCA | 370 nm | µmol carbonyl/mg but expressed as percent to control | |
| 800 µg protein | Ratio n.a. | Washing with ethanol–ethyl acetate (1:1) | ||||
| For 1 h in the dark | 6 M guanidine | |||||
| Cow | Oxidized BSA | 10 mM DNPH (in 2 M HCl) | 20% TCA | 376 nm | Standard curve: 2–27 nmol/mg | |
| 1 mg | Ratio (1:1) | Washing with ethanol–ethyl acetate (1:1) | ||||
| 1 h at RT | 6 M guanidine | |||||
| Horse | Heart myoglobin | 10 mM DNPH (in 2.5 M HCl) | Centrifugation | 400 nm | After TEMPOL incubation the myoglobin N-terminus underwent oxidative deamination in which the Gly N-terminal amino group was replaced with a free carbonyl group | |
| Concentration n.a. | Ratio (1:1) | PD-10 column | HPLC analysis | |||
| 15 min in the dark | ||||||
| Hamster | Liver supernatant | 10 mM DNPH (in 2.5 M HCl) | 20% TCA | 370 nm | 2.25–3.74 nmol/mg | |
| Concentration n.a. | Ratio (1:1) | Washing with ethanol–ethyl acetate (1:1) | ||||
| 30 min at RT | Dissolved 6% SDS |
Some levels could only be drawn from figures. The concentration is therefore not the exactly measured one.
Fig. 4Final number of publications highlighted in Tables 2–4. As described in the search strategy, PubMed was accessed in November 2013 to view the publications of Levine, Shacter et al., Keller et al., and Buss et al. as well as all publications citing one of these original method publications. The extracted publications were grouped into categories (review, bacteria, plants; did not apply method; commercial kit; method applied but not described; relevant publication describing sample preparation etc.).
Measurements of protein carbonyls by immunoblotting.
| Species | Sample preparation | Derivatization | Gel, PAGE, membrane proteins amount, transfer/blot | Antibody | Level/result | Refs. |
|---|---|---|---|---|---|---|
| Ratio (sample/DNP) | ||||||
| Conditions | ||||||
| Human | Heparin plasma | 10 mM DNPH (in 10% TCA) | SDS-PAGE (4–12% gradient) | Monoclonal anti-DNP IgE (Sigma), biotinylated rat anti-mouse IgE | Method description, different oxidized proteins | |
| Nitrocellulose membrane | (Southern Biotechnologies), and biotin–avidin-peroxidase complex (Vector Laboratories) | |||||
| Blotting by standard procedures | ||||||
| Human | Serum | Post-electrophoresis derivatization | 10% SDS-PAGE | Anti-DNP (Molecular Probes) | To compare pre- and post-electrophoresis derivatization | |
| 0.5 mM DNPH | Protein amount n.a. | Goat anti-rabbit HRP-conjugate (Sigma) | ||||
| Nitrocellulose and PVDF membranes | ||||||
| Human | Lysed SH-SY5Y cell supernatant | 20 mM DNPH (in 2 M HCl) sample in 12% SDS (1:1) | SDS-PAGE (10% and 15%) | Polyclonal rabbit anti-DNP (Invitrogen) | Exposure of Sphingosine Kinase 1 to TNFα caused substantial carbonylation | |
| Ratio (1:1) | 30 µg soluble and 5 µg purified protein | Anti-rabbit HRP-conjugate | ||||
| For 45 min at 25 °C | PVDF membrane | |||||
| Precipitation of protein in chloroform/methanol | ||||||
| Rabbit | Purified muscle actin, total protein of SH-SY5Y cell extracts, and actin immune-precipitated from SH-SY5Y cells centrifuged soluble protein from cell extracts | 20 mM DNPH (in 2 M HCl) | SDS-PAGE and 2D Nu-PAGE (4–12%) | Polyclonal rabbit anti-DNP (Invitrogen) | Considerable actin carbonylation in SH-SY5Y cells acutely exposed to TNFα or IL-1β | |
| Sample in 12% SDS (1:1) | 30–50 µg soluble and 5 µg purified protein | Secondary Ab n.a. | ||||
| (30 min, 25 °C) | PVDF membrane | |||||
| Ratio (1:1) | ||||||
| Human | Acute promyelocytic leukemia (APL)-derived NB-4 cells soluble protein fraction | 10 mM DNPH | 12% gel | Anti-DNP | Treatment of NB4 cells with increasing concentrations (0.5–6 M) of As2O3 leads to increased protein carbonyls | |
| Sample in lysis buffer containing 6% SDS (pH 7.2) | Ratio (1:1, 15 µl:14 µl) | Nu-PAGE | AP-conjugated anti-rabbit IgG | |||
| For 10 min at RT | 25 µg protein | |||||
| Nitrocellulose membrane | ||||||
| Human | HeLa cell extract | 10 mM DNPH | Dot-Blot microfiltration apparatus and TransBlot transfer membrane (Bio-Rad) | Anti-DNP (Dako) | Slightly increased carbonylation in cells lacking glutaredoxin 1 | |
| 1 µg/µl | Ratio (1:4) | AP-conjugated anti-rabbit (Dako) | ||||
| 30 min at RT | ||||||
| Human | Alzheimer’s disease brain homogenates | 20 mM DNPH | % n.a. | Rabbit anti-DNP (Millipore) | Different proteins carbonylated in AD on comparison to age-matched controls | |
| Ratio (1:4) | SDS-PAGE | Goat anti-rabbit IgG (Sigma) | ||||
| 20 min at 25 °C | 150 µg protein | |||||
| Nitrocellulose membrane | ||||||
| Semi-dry transfer | ||||||
| Human | Bronchoalveolar lavage (BAL) fluid | OxyBlot kit (Chemicon Inc.) | 10% SDS-PAGE | Anti-DNP | Amount of carbonylated albumin per mg total albumin in BAL fluid was four times higher in older current smokers and three times higher in older former smokers than in age matched non-smokers | |
| Human | Colon cells (SW620) | Post-electrophoresis derivatization: 10 µg/ml DNPH (≙0.5 mM) in 2 M HCl | 5 µg protein/slot | Anti-DNP-KLH, rabbit IgG (H&L) fraction (Molecular Probes) | Development of an immunochemical technique for the quantification of carbonyl groups in protein samples from small tissue samples and cell cultures | |
| min at RT | PVDF membrane | Peroxidase-conjugated F(ab′)2 fragment donkey anti-rabbit IgG (H&L) fraction (Jackson Immunoresearch Laboratories) | ||||
| Slot-blot | ||||||
| Mouse and human | C57BL mouse tissue and human fibroblasts | DNPH/TFA from OxyBlot Kit (Oncor) | % n.a. | From the OxyBlot Kit | Improve methods | |
| Ratio (1:1) | SDS-PAGE | |||||
| 15 min at RT | Protein amount n.a. | |||||
| Nitrocellulose and PVDF membrane | ||||||
| Semi-dry blotting | ||||||
| Mouse | Cortical neuron homogenate and lysate | n.a. | 12.5% SDS-PAGE | Anti-DNP kit (Chemicon Inc.) | Relative to control | |
| 20 µg | 20 µg | |||||
| Nitrocellulose membrane | ||||||
| Mouse | Isolated collagen | 0.5 mM DNPH | 6% slab gel | Rabbit anti-DNP (Sigma) | Induced damage to collagen after treatment with pefloxacin | |
| Ratio (1:1) | SDS-PAGE | AP-conjugated goat anti-rabbit IgG (Sigma) | ||||
| 1 h at RT | 50, 15 or 7 µg collagen | |||||
| PVDF membrane (Sigma) | ||||||
| Trans-Blot apparatus | ||||||
| Mouse | Mitochondria from Heat Shock factor 1 (Hsf1) knockout mice | 10 mM DNPH | % n.a. | Rabbit anti-DNP (Sigma) | Higher extent of carbonylation in mitochondrial proteins of | |
| Ratio n.a. | SDS-PAGE | HRP-labeled goat anti-rabbit IgG | ||||
| 60 min at RT | Protein amount n.a. | |||||
| PVDF membrane | ||||||
| Mini trans-blot electrophoretic transfer cell (Bio-Rad) | ||||||
| Rat | Serum | 20 mM DNPH (in 10% TFA) | % n.a. | Goat anti-DNP (Bethyl Laboratories Inc.) | Changes in serum levels of total protein carbonylation correspond to cardio-protective activity | |
| Ratio (1:1) | SDS-PAGE | Donkey anti-goat IRDye 800CW (Li-COR) | ||||
| 10 min at RT | 5 µg protein | |||||
| PVDF membrane | ||||||
| Rat | Mitochondria from head homogenate (male, weanling Sprague-Dawley rats) | OxyBlot Kit | 10% SDS-PAGE | Anti-DNP (OxyBlot Kit) | Comparison between rats with copper deficient diets (reduced carbonyls in copper deficiency) | |
| 6 µg protein | HRP-coupled anti-sheep IgG (Amersham) | |||||
| PVDF membrane | ||||||
| Semi-dry transfer | ||||||
| Rat | Ovary tissue sections | 10 mM DNPH (in 10% TFA) | 12% SDS-PAGE | Rabbit anti-DNP | Increased protein carbonyls were detected in ovaries of rats exposed to tetrachlorethylene water for 2 weeks compared to controls | |
| Ratio n.a. | 25 µg protein | Biotinylated anti-rabbit (Vectastain ABC-AP kit) | ||||
| 45 min | PVDF membrane | |||||
| Tank blot | ||||||
| Rat and cow | Histones from PC12 cells (rat) and thymus, liver, spleen (bovine) | 10 mM DNPH (in 10% TFA) | % n.a. | Anti-DNP (Dako) | Higher carbonylation in untreated histone H1 in comparison to core histone | |
| Ratio (1:1) | SDS-PAGE | Goat anti-rabbit conjugated with HRP (Jackson Immunoresearch Laboratories) | ||||
| 20 min at RT | 5 µg protein | |||||
| Nitrocellulose membrane | ||||||
| Semi-dry blot | ||||||
| Cow | Oxidized BSA | 0.5 mM DNPH | % n.a. | Anti-DNP antisera (Dako) | Development of an immunochemical assay | |
| Ratio (1:1) | SDS-PAGE | Mouse anti-rabbit IgG conjugated with AP (Jackson Immunoresearch Laboratories) | ||||
| 1 h at RT | Protein amount n.a. | |||||
| Nitrocellulose membrane | ||||||
| Glutamine synthetase | 20 mM DNPH and 0.5% TFA in 92.5% DMSO | Dot-blot and Western blot (14% and 8–16%) | Goat anti-DNP (Bethyl Laboratories Inc.) | Comparison between dot blot and Western blot | ||
| Ratio n.a. | PVDF membrane | Donkey anti-goat IRDye 800CW (Li-COR) | ||||
| 15 min at RT |
Determination of protein carbonyls by ELISA.
| Species | Sample preparation | Derivatization | Antibody | Plate producer | Level* | Ref |
|---|---|---|---|---|---|---|
| Human | Plasma from healthy and critically ill patientsdiluted to 4 mg/ml | 10 mM DNPH (in 6 M guanidine HCl, 0.5 M potassium phosphate buffer, pH 2.5) | Biotinylated anti-DNP (Molecular Probes) | MaxiSorp (Nunc) | 0.06–0.75 nmol/mg | |
| Ratio sample/DNPH (1:4) | Streptavidin-biotinylated-HRP (Amersham) | |||||
| 45 min at RT | ||||||
| Human | Plasma from sepsis patients vs controls | n.a. | Biotin-conjugated polyclonal anti-DNP IgG | n.a. | 0.32–0.45 nmol/mg | |
| Dilution n.a. | Streptavidin-conjugated HRP | |||||
| Human | Citrate-plasma from schizophrenia patients and healthy volunteers | n.a. | n.a. | n.a. | 0.178–0.482 nmol/mg | |
| Dilution n.a | ||||||
| Human | Heparin and EDTA plasma and urine | n.a. | n.a. | n.a. | Significantly higher concentration in blood of subway workers and bus drivers than in office workers (17 and 18 vs. 15 nmol/ml) | |
| Dilution n.a. | ||||||
| Human | Plasma from 71 hepatocellular carcinoma patients and 694 controls | n.a. | n.a. | n.a. | 0.11–1.41 nmol/mg | |
| Dilution n.a. | ||||||
| Human | Plasma of chronic obstructive pulmonary disease (COPD) patients | n.a. | Polyclonal rabbit anti-DNP (Molecular Probes) | MaxiSorp (Nunc) | 17.9±2.9 nmol/mg | |
| 4 mg/ml | HRP-conjugate (Amersham) | |||||
| Human | Plasma from participants of the New York Early Lung Cancer Action Project | n.a. | Polyclonal rabbit anti-DNP (Molecular Probes) | n.a. | ~17 nmol/ml | |
| 4 mg/ml | HRP-conjugate (Amersham) | |||||
| Human | Plasma | 10 mM DNPH (in 6 M guanidine–HCl, 0.5 M potassium phosphate, pH 2.5) | Biotinylated anti-DNP (Molecular Probes) | ELISA (Corning Costar) | ~11–15.3 nmol/mg | |
| 4 mg/ml | Ratio and conditions n.a. | Streptavidin–biotin HRP (Amersham) | ||||
| Human | Serum from middle-aged obese subjects | Concentration and conditions n.a. | n.a. | n.a. | 0.12 arb. u. | |
| 4 mg/ml | Ratio (1:4) | |||||
| Human | Heparin plasma | 0.05 mM DNPH (in H3PO4, pH 6.2) | Anti-DNP (Sigma) | n.a. | Method for measuring protein carbonyl in samples with low amounts of protein | |
| 5 µg/ml | 45 min at RT in the dark | Anti-rabbit HRP-linked IgG (H&L, Upstate Cell Signaling) | ||||
| Human | Plasma and LDL | n.a. | Anti-DNP (Dako) | n.a. | Modification of method | |
| Dilution n.a. | Goat anti-rabbit IgG peroxidase conjugate (Sigma) | |||||
| Human | Plasma | n.a. | n.a. | n.a. | 0.1–0 5 nmol carbonyl groups fibrinogen/mg of plasma proteins | |
| Dilution n.a. | ||||||
| Human | Plasma from women with preeclampsia and controls | 45 min at RT | Rabbit anti-DNP-KLH (Invitrogen) | n.a. | Significantly higher concentration in cases than in controls | |
| Dilution n.a. | HRP-conjugated porcine anti-rabbit IgG (Dako A/S) | |||||
| Human | Plasma | n.a. | Biotinylated anti-DNP (Molecular Probes) | n.a. | ||
| 4 mg/ml | Streptavidin-biotinylated HRP-conjugate (Amersham) | |||||
| Human | K562 cell lysates (human chronic myelogenous leukemia) | n.a. | Rabbit anti-DNP IgG antiserum (Sigma) | n.a. | Relation to control | |
| 1 mg/ml in lysis buffer with 1 mM BHT | Monoclonal anti-rabbit peroxidase-conjugated IgG (Sigma) | |||||
| Human | Parenchymal lung tissue of current smokers with chronic obstructive pulmonary disease | n.a. | Plate was pre-incubated with mouse anti-HSA before addition of samples | n.a. | 0.5–5 carbonyl residues/HSA molecule | |
| Dilution n.a. | rabbit anti-DNP | |||||
| Anti-rabbit HRP-conjugate | ||||||
| Human | MRC-5-fibroblast cell lysates (fetal lung) | n.a. | Anti-DNP rabbit-IgG-antiserum (Sigma) | n.a. | ~1.5–3.2 nmol/mg | |
| 4 mg/ml | Monoclonal anti-rabbit-IgG-peroxidase conjugated (Sigma) | |||||
| Mouse | Brain, liver, heart and spleen homogenates from 6-week-old male DDY mice | 10 mM DNPH (in 2 M HCl) | n.a. | n.a. | Relation to control | |
| 1 mg/ml | For 1 h at RT | |||||
| Ratio n.a. | ||||||
| Mouse | Heart tissue homogenate of SAMP8 mice | n.a. | Rabbit anti-DNP IgG-antiserum (Sigma Aldrich) | n.a. | 664±37 nmol/g (high-polyphenol diet) and 958±70 (low-polyphenol diet) nmol/g | |
| Dilution n.a. | Monoclonal anti-rabbit IgG peroxidase conjugate (Sigma Aldrich) | |||||
| Mouse | Mesenchymal stem cells derived from adipose tissue of C57/Black6 mice | n.a. | n.a. | n.a. | 4–32 Carbonyls/mg protein | |
| Dilution n.a. | ||||||
| Mouse | Brain homogenate from ApoD-knockout mice | n.a. | Biotinylated anti-DNP (Molecular Probes) | n.a. | Relation to control | |
| Dilution n.a. | Streptavidin-biotinylated HRP (Amersham) | |||||
| Mouse | Isolated mitochondria from livers of Bcs1lG/G mice | Concentration and ratio n.a. | Anti-DNP (Invitrogen) | n.a. | 1.09±0.36 relative amount | |
| Dilution n.a. | 45 min at RT | Swine anti-rabbit IgG-HRP (Dako A/S) | ||||
| Mouse | Retinal pigmented epithelial cell lysates | 10 mM DNPH (in 6 M guanidine–HCl, 0.5 M potassium phosphate, pH 2.5) | Polyclonal rabbit anti-DNP (Molecular Probes) | MaxiSorp (Nunc) | 0.6–1.2 nmol | |
| 4 mg/ml | Ratio (1:4) | HRP-conjugate (Amersham) | ||||
| 45 min at RT | ||||||
| Mouse | RAW264.7 murine macrophage-like cells | Kit from Cell Biolabs | Kit from Cell Biolabs | Kit from Cell Biolabs | Results not significant | |
| Dilution n.a. | ||||||
| Mouse | HT22 cell lysates4 mg/ml in lysis buffer with 1 mM BHT | n.a. | Rabbit anti-DNP IgG antiserum (Sigma) | n.a. | 6.5–9.0 pmol/mg | |
| Monoclonal peroxidase-conjugated anti-rabbit IgG (Sigma) | ||||||
| Rat | Ileal mucosa of salmonella infected rats | n.a. | Biotinylated anti-DNP (Molecular Probes), streptavidin-biotinylated HRP (Amersham) | MaxiSorp (Nunc) | 0.1–0.2 nmol/mg | |
| 4 mg/ml | ||||||
| n.a. | Ferritin | (10 mM in 6 M guanidine HCl, 0.5 M potassium phosphate, pH 2.5) | Biotinylated anti-DNP | MaxiSorp(Nunc) | 0.55–1.0 nmol/mg | |
| Dilution n.a. | Ratio (1:3) | Anti-rabbit-IgG-peroxidase (γ-chain specific) | ||||
| 45 min at RT |